⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APRE News
Aprea Therapeutics, Inc. Common stock
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
globenewswire.com
APRE
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
globenewswire.com
APRE
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
globenewswire.com
APRE
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
globenewswire.com
APRE
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
globenewswire.com
APRE
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
globenewswire.com
APRE
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
globenewswire.com
APRE
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
globenewswire.com
APRE